Epidermolysis hyperkeratosis (EH) is a rare skin disorder characterized by blistering, redness, and inflammation of the skin. It is caused by mutations in the genes responsible for the formation of the protein keratin, which makes up the outermost layer of the skin. Although the exact cause of EH is unknown, it is thought to be an inherited disorder. The symptoms of EH can range from mild to severe, and can affect individuals of any age. While treatments are available to manage the symptoms, there is currently no known cure for the disorder.
Epidermolysis hyperkeratosis (EH) is a rare skin disorder in which the skin becomes fragile and easily damaged. It is caused by mutations in the genes responsible for the formation of the protein keratin, which makes up the outermost layer of the skin. These mutations cause the skin to become extremely fragile and prone to blistering and inflammation. EH can affect individuals of any age, and the severity of the disorder can vary from mild to severe. Common symptoms of EH include redness, blistering, and inflammation of the skin. In some cases, the skin may also become thickened and form calluses.
Diagnosis of EH is typically made through a physical exam and a review of the patient’s medical history. In some cases, a biopsy may be performed to confirm the diagnosis. Treatment of EH is typically focused on managing the symptoms and preventing further damage to the skin. This may include the use of moisturizers, topical corticosteroids, or other medications to reduce inflammation and blistering. In some cases, surgery may be necessary to remove thickened skin or to repair damaged tissue.
Although there is currently no known cure for EH, researchers are actively working to develop new treatments and therapies. The development of gene therapy, stem cell therapy, and other treatments are currently being explored as potential treatments for EH. In addition, researchers are working to better understand the genetic basis of EH. By identifying the specific genes responsible for the disorder, researchers hope to develop new treatments that can target the underlying cause of the disorder.
Epidermolysis hyperkeratosis is a rare skin disorder that can cause blistering, redness, and inflammation of the skin. Although there is currently no known cure for the disorder, treatments are available to manage the symptoms and prevent further damage to the skin. Researchers are actively working to develop new treatments and therapies for EH, and to better understand the genetic basis of the disorder. With continued research, it is hoped that a cure for EH will one day be discovered.
1.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
2.
New drug combination shows good results in patients with HPV-negative head and neck cancer
3.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
4.
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
5.
Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant
1.
Environmental Carcinogen Exposure Screening: Advances, Clinical Implications, and Guideline-Based Approaches
2.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
3.
Progressive Insights in Hematology in the Digital Era
4.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
5.
The importance of understanding normal serum osmolality
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation